...
search icon
orgo-img

Organogenesis Holdings Inc, Common Stock

ORGO

NAQ

$2.97

-$0.04

(-1.33%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$384.37M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
593.23K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.85
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.28 L
$6.71 H
$2.97

About Organogenesis Holdings Inc, Common Stock

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameORGOSectorS&P500
1-Week Return-1.98%0.86%-1.29%
1-Month Return-31.41%-2.58%10.63%
3-Month Return-6.6%-10.87%-2.43%
6-Month Return-26.67%-8.73%-2.14%
1-Year Return5.32%-10.19%10%
3-Year Return-48.35%0.5%46.86%
5-Year Return-11.08%32.08%97.3%
10-Year Return-69.54%75.49%174.39%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue338.30M468.06M450.89M433.14M482.04M[{"date":"2020-12-31","value":70.18,"profit":true},{"date":"2021-12-31","value":97.1,"profit":true},{"date":"2022-12-31","value":93.54,"profit":true},{"date":"2023-12-31","value":89.86,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue87.32M114.20M105.02M106.48M115.74M[{"date":"2020-12-31","value":75.44,"profit":true},{"date":"2021-12-31","value":98.67,"profit":true},{"date":"2022-12-31","value":90.74,"profit":true},{"date":"2023-12-31","value":92,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit250.98M353.86M345.87M326.66M366.30M[{"date":"2020-12-31","value":68.52,"profit":true},{"date":"2021-12-31","value":96.6,"profit":true},{"date":"2022-12-31","value":94.42,"profit":true},{"date":"2023-12-31","value":89.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin74.19%75.60%76.71%75.42%75.99%[{"date":"2020-12-31","value":96.71,"profit":true},{"date":"2021-12-31","value":98.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.32,"profit":true},{"date":"2024-12-31","value":99.06,"profit":true}]
Operating Expenses223.56M280.94M323.57M314.13M367.58M[{"date":"2020-12-31","value":60.82,"profit":true},{"date":"2021-12-31","value":76.43,"profit":true},{"date":"2022-12-31","value":88.03,"profit":true},{"date":"2023-12-31","value":85.46,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income27.41M72.92M22.30M12.53M(1.28M)[{"date":"2020-12-31","value":37.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":30.59,"profit":true},{"date":"2023-12-31","value":17.18,"profit":true},{"date":"2024-12-31","value":-1.76,"profit":false}]
Total Non-Operating Income/Expense(20.21M)(16.37M)(4.03M)(3.79M)(3.07M)[{"date":"2020-12-31","value":-2021500000,"profit":false},{"date":"2021-12-31","value":-1636800000,"profit":false},{"date":"2022-12-31","value":-403100000,"profit":false},{"date":"2023-12-31","value":-379100000,"profit":false},{"date":"2024-12-31","value":-306800000,"profit":false}]
Pre-Tax Income18.48M63.79M20.28M10.39M(2.81M)[{"date":"2020-12-31","value":28.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":31.8,"profit":true},{"date":"2023-12-31","value":16.29,"profit":true},{"date":"2024-12-31","value":-4.4,"profit":false}]
Income Taxes530.00K(31.12M)4.75M5.45M(3.67M)[{"date":"2020-12-31","value":9.73,"profit":true},{"date":"2021-12-31","value":-571.25,"profit":false},{"date":"2022-12-31","value":87.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-67.34,"profit":false}]
Income After Taxes17.95M94.90M15.53M4.95M861.00K[{"date":"2020-12-31","value":18.91,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.37,"profit":true},{"date":"2023-12-31","value":5.21,"profit":true},{"date":"2024-12-31","value":0.91,"profit":true}]
Income From Continuous Operations17.95M94.90M15.53M13.00M861.00K[{"date":"2020-12-31","value":18.91,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.37,"profit":true},{"date":"2023-12-31","value":13.7,"profit":true},{"date":"2024-12-31","value":0.91,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income17.23M94.20M15.53M4.95M861.00K[{"date":"2020-12-31","value":18.29,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.49,"profit":true},{"date":"2023-12-31","value":5.25,"profit":true},{"date":"2024-12-31","value":0.91,"profit":true}]
EPS (Diluted)0.120.710.180.040.18[{"date":"2020-12-31","value":16.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":24.79,"profit":true},{"date":"2023-12-31","value":5.03,"profit":true},{"date":"2024-12-31","value":25.75,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ORGO
Cash Ratio 1.69
Current Ratio 4.12
Quick Ratio 3.67

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ORGO
ROA (LTM) 0.70%
ROE (LTM) -4.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ORGO
Debt Ratio Lower is generally better. Negative is bad. 0.21
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.52

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ORGO
Trailing PE NM
Forward PE 12.32
P/S (TTM) 0.83
P/B 1.47
Price/FCF NM
EV/R 0.91
EV/Ebitda 30.88

FAQs

What is Organogenesis Holdings Inc share price today?

Organogenesis Holdings Inc (ORGO) share price today is $2.97

Can Indians buy Organogenesis Holdings Inc shares?

Yes, Indians can buy shares of Organogenesis Holdings Inc (ORGO) on Vested. To buy Organogenesis Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ORGO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Organogenesis Holdings Inc be purchased?

Yes, you can purchase fractional shares of Organogenesis Holdings Inc (ORGO) via the Vested app. You can start investing in Organogenesis Holdings Inc (ORGO) with a minimum investment of $1.

How to invest in Organogenesis Holdings Inc shares from India?

You can invest in shares of Organogenesis Holdings Inc (ORGO) via Vested in three simple steps:

  • Click on Sign Up or Invest in ORGO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Organogenesis Holdings Inc shares
What is Organogenesis Holdings Inc 52-week high and low stock price?

The 52-week high price of Organogenesis Holdings Inc (ORGO) is $6.71. The 52-week low price of Organogenesis Holdings Inc (ORGO) is $2.28.

What is Organogenesis Holdings Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Organogenesis Holdings Inc (ORGO) is 1.47

What is the Market Cap of Organogenesis Holdings Inc?

The market capitalization of Organogenesis Holdings Inc (ORGO) is $384.37M

What is Organogenesis Holdings Inc’s stock symbol?

The stock symbol (or ticker) of Organogenesis Holdings Inc is ORGO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top